Goldman Sachs analyst Paul Choi upgraded Vir Biotechnology to Buy from Neutral with a price target of $53, up from $41. The company will report VIR-2482 data in mid-2023, which should show meaningfully better efficacy than currently approved and rival pipeline-stage flu vaccines and consequently to drive material upward revisions to consensus estimates, the analyst tells investors in a research note. Goldman sees a "compelling risk/reward" on shares of Vir into the day. It believes the readout represents "an underappreciated catalyst that could drive a major new leg of growth."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VIR:
- Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- Vir Biotechnology appoints Sung Lee as Chief Financial Officer
- Vir Biotechnology Announces Amended Collaboration Agreement with GSK
- Vir Biotechnology announces amended collaboration pact with GSK
- Vir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
